Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches. Rainbow Coral Corp. (OTCBB:RBCC), an emerging biotechnology company, is hard at work identifying and targeting promising new stem-cell treatments for commercialization.

As the world's population ages and the economic might of emerging countries such as China and India blossoms, the market is increasing daily for new and effective cures to old ailments. RBCC plans to capitalize on recent growth in the biosciences sector by commercializing advanced-stage research with the potential to produce new treatments.

RBCC is aiming high. The company's current target, n3D Biosciences, has developed a breakthrough cell-culturing system that allows scientists to grow 3D stem cells that behave much more similarly to cells found in the body. This product may directly assist with advanced discoveries to find cures for common injuries and diseases.

With the help of its new allies in BioHouston, RBCC plans to identify new targets on the cutting-edge of biotechnology for acquisition and joint venture.

Through its biotech division, Rainbow BioSciences, RBCC is working to develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc.(NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Elan Corp. (NYSE: ELN).

For more information on Rainbow BioSciences' biotechnology initiative, please visit www.rainbowbiosciences.com/investors.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com